01.11.2022
— cardiac ion channel, channelopathy, ion channel, ion channel cancer, ion channel pain, ion channels, neuroscience, safety pharmacology, Sophion
New ion channel posters
以前弊社が作成した” Cardiac Ion Channels”ポスターを 覚えていらっしゃいますでしょうか。このたび、追加で2種類のポスターを作成しました。”Ion Channels in Cancer” および”Ion Channels in Pain”です。ご希望の方にポスターを郵送させていただきます。
ゲッティンゲン・大学医療センターからFitzwilliam Seibertz博士をお招きし、「Differentiation of induced pluripotent stem cells into cardiomyocytes with a focus on maturity-induced IK1 development」と題した講演をしていただきます。
しかしBiolin Scientificという大企業への統合は商業的には成功せず、2017年のマネジメント・バイアウト(MBO)によって再びSophionは自ら「家の主」となりました。その後、皆さまもご存じの通り、事業は再び加速します。QPatch II 48、QPatch II 16、Qube Opto、オンラインV½推定、そして新たな改良が施された温度コントローラーの導入により、当社のAPCシステムは今まで以上に使いやすくなり、より高度な機能を備えることになります。直近4年間において前年比2桁の成長を遂げたことで、これまで以上に多くのEUプロジェクト、業界内におけるパートナーシップ、そして学術的なコラボレーションが行われている、大変興味深い新しい状況に今日の当社はあります。
For Sophion it has been a year with many changes, a lot of news and countless achievements. It has also, by far, been the best year in the history of Sophion Bioscience and on behalf of the whole Sophion Bioscience team we would like to thank all our partners and customers for their continued support. Read more about 2017 seen from our perspective here “Sophion 2017 in brief”
Contact
25.09.2017
— electrophysiology, employees, new employee, Sophion
New faces at Sophion
To meet the increasing demand of new application development and customer support, we have hired two new application specialists.
Kim Boddum has a PhD in neuropharmacology and comes from a post doc at the Department of Biomedical Sciences at the Uni of CPH. Kim has for the past 7-8 years worked on membrane receptors and ion channels function and pharmacology.
Kadla Røskva Rosholm has a PhD in Nanoscience working on high-throughput fluorescence-based cell assays. Also she been done two post docs working on electrophysiological and fluorescence methodologies to investigate the molecular mechanism of ion-channel signaling.
You can meet Dr. Kadla Røskva Rosholm and Dr. Kim Boddum at customer sites, demos or conferences.
Contact
04.05.2017
— Sophion
Sophion in the US is moving to Boston
We are happy to announce that we will be moving our US facilities to Boston over the summer. The Boston offices and laboratory will, when finished, be fully operational for application and assay development, and as a training and demonstration laboratory for customers and development partners. Although our current laboratory in New Jersey was conveniently close to Manhattan and the Yankee Stadium, we have for the last couple of years wanted to move to Boston. The recent split from Biolin Scientific gave us that opening. Keep the line open and wait for the invitation for housewarming during the autumn.
Voltage- and current clamp on induced pluripotent cardiomyocytes with Qube 384
Action potentials are induced in both HL-1 mouse atrial cardiomyocytes and Axiogenesis Cor.4U iPS cell-derived cardiomyocytes.
Voltage- and current clamp on induced pluripotent cardiomyocytes with Qube 384. Action potentials are induced in both HL-1 mouse atrial cardiomyocytes and Axiogenesis Cor.4U iPS cell-derived cardiomyocytes. Qube can combine voltage clamp and current clamp in the same sweep for added experimental control. Click here to read more.